Compare Duolingo Inc (DUOL) vs Moderna, Inc. (MRNA) Price & Performance

Duolingo (DUOL) trades at $149.92, down 1.19% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $0.66 versus $0.60, continuing a pattern of earnings outperformance. Revenue growth remains robust at 39% year-over-year for 2025, reaching $1.04 billion, while maintaining exceptional profitability with a 35.87% net income margin. Technical indicators show a bullish moving average configuration despite neutral oscillators.

Duolingo presents a compelling growth story with accelerating revenue expansion and industry-leading margins, though valuation multiples appear elevated with a P/E of 17.87 and P/S of 6.47. Key risks include CEO share sales totaling $4.3 million in September 2026 and competitive pressures in the edtech space. Analyst consensus leans cautious with 54% hold ratings, suggesting the stock may be fairly valued near current levels despite strong operational performance.

Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.

While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.